Amy Armstrong

No ORCID on file · 1 paper in corpus

nonrandomized-trial 2018

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.04.572

OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at lea…